Risk of Upgrading from Prostate Biopsy to Radical Prostatectomy Pathology-Does Saturation Biopsy of Index Lesion during Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy Help?

被引:96
作者
Calio, Brian P. [1 ]
Sidana, Abhinav [1 ,6 ]
Sugano, Dordaneh [1 ]
Gaur, Sonia [2 ]
Maruf, Mahir [1 ]
Jain, Amit L. [1 ]
Merino, Maria J. [3 ]
Choyke, Peter L. [2 ]
Wood, Bradford J. [4 ,5 ]
Pinto, Peter A. [1 ]
Turkbey, Baris [2 ]
机构
[1] NCI, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA
[2] NCI, Mol Imaging Program, NIH, Bethesda, MD 20892 USA
[3] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[4] NCI, Ctr Intervent Oncol, NIH, Bethesda, MD 20892 USA
[5] NIH, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA
[6] Univ Cincinnati, Coll Med, Div Urol, Cincinnati, OH USA
关键词
prostatic neoplasms; image-guided biopsy; neoplasm grading; pathology; surgical; risk; SYSTEMATIC BIOPSY; CANCER-DETECTION; GLEASON SCORES; SPECIMENS; DIAGNOSIS; ACCURATE; GUIDANCE;
D O I
10.1016/j.juro.2017.10.048
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We sought to determine whether saturation of the index lesion during magnetic resonance imaging-transrectal ultrasound fusion guided biopsy would decrease the rate of pathological upgrading from biopsy to radical prostatectomy. Materials and Methods: We analyzed a prospectively maintained, single institution database for patients who underwent fusion and systematic biopsy followed by radical prostatectomy in 2010 to 2016. Index lesion was defined as the lesion with largest diameter on T2-weighted magnetic resonance imaging. In patients with a saturated index lesion transrectal fusion biopsy targets were obtained at 6 mm intervals along the long axis of the index lesion. In patients with a nonsaturated index lesion only 1 target was obtained from the lesion. Gleason 6, 7 and 8-10 were defined as low, intermediate and high risk, respectively. Results: Included in the study were 208 consecutive patients, including 86 with a saturated and 122 with a nonsaturated lesion. Median patient age was 62.0 years (IQR 10.0) and median prostate specific antigen was 7.1 ng/ml (IQR 8.0). The median number of biopsy cores per index lesion was higher in the saturated lesion group (4 vs 2, p < 0.001). The risk category upgrade rate from systematic only, fusion only, and combined fusion and systematic biopsy results to prostatectomy was 40.9%, 23.6% and 13.8%, respectively. The risk category upgrade from combined fusion and systematic biopsy results was lower in the saturated than in the nonsaturated lesion group (7% vs 18%, p = 0.021). There was no difference in the upgrade rate based on systematic biopsy between the 2 groups. However, fusion biopsy results were significantly less upgraded in the saturated lesion group (Gleason upgrade 20.9% vs 36.9%, p = 0.014 and risk category upgrade 14% vs 30.3%, p = 0.006). Conclusions: Our results demonstrate that saturation of the index lesion significantly decreases the risk of upgrading on radical prostatectomy by minimizing the impact of tumor heterogeneity.
引用
收藏
页码:976 / 981
页数:6
相关论文
共 28 条
  • [1] Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies
    Borboroglu, PG
    Comer, SW
    Riffenburgh, RH
    Amling, CL
    [J]. JOURNAL OF UROLOGY, 2000, 163 (01) : 158 - 162
  • [2] Changes in prostate cancer detection rate of MRI-TRUS fusion vs systematic biopsy over time: evidence of a learning curve
    Calio, B.
    Sidana, A.
    Sugano, D.
    Gaur, S.
    Jain, A.
    Maruf, M.
    Xu, S.
    Yan, P.
    Kruecker, J.
    Merino, M.
    Choyke, P.
    Turkbey, B.
    Wood, B.
    Pinto, P.
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2017, 20 (04) : 436 - 441
  • [3] Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours
    Corcoran, Niall M.
    Hovens, Chris M.
    Hong, Matthew K. H.
    Pedersen, John
    Casey, Rowan G.
    Connolly, Stephen
    Peters, Justin
    Harewood, Laurence
    Gleave, Martin E.
    Goldenberg, S. Larry
    Costello, Anthony J.
    [J]. BJU INTERNATIONAL, 2012, 109 (05) : 660 - 664
  • [4] When to biopsy and when to stop biopsying
    Djavan, B
    Remzi, M
    Marberger, M
    [J]. UROLOGIC CLINICS OF NORTH AMERICA, 2003, 30 (02) : 253 - +
  • [5] Biopsy Gleason score: How does it correlate with the final pathological diagnosis in prostate cancer?
    Fernandes, ET
    Sundaram, CP
    Long, R
    Soltani, M
    Ercole, CJ
    [J]. BRITISH JOURNAL OF UROLOGY, 1997, 79 (04): : 615 - 617
  • [6] Discrepancies between Gleason scores of needle biopsy and radical prostatectomy specimens
    Fukagai, T
    Namiki, T
    Namiki, H
    Carlile, RG
    Shimada, M
    Yoshida, H
    [J]. PATHOLOGY INTERNATIONAL, 2001, 51 (05) : 364 - 370
  • [7] Percutaneous MR-guided cryoablation of prostate cancer: initial experience
    Gangi, Afshin
    Tsoumakidou, Georgia
    Abdelli, Omar
    Buy, Xavier
    de Mathelin, Michel
    Jacqmin, Didier
    Lang, Herv
    [J]. EUROPEAN RADIOLOGY, 2012, 22 (08) : 1829 - 1835
  • [8] PI-RADSv2: How We Do It
    Greer, Matthew D.
    Choyke, Peter L.
    Turkbey, Baris
    [J]. JOURNAL OF MAGNETIC RESONANCE IMAGING, 2017, 46 (01) : 11 - 23
  • [9] Is an Initial Saturation Prostate Biopsy Scheme Better than an Extended Scheme for Detection of Prostate Cancer? A Systematic Review and Meta-analysis
    Jiang, Xingkang
    Zhu, Shimiao
    Feng, Guowei
    Zhang, Zhihong
    Li, Changying
    Li, Hui
    Wang, Chao
    Xu, Yong
    [J]. EUROPEAN UROLOGY, 2013, 63 (06) : 1031 - 1039
  • [10] Focal or subtotal therapy for early stage prostate cancer
    Jones J.S.
    [J]. Current Treatment Options in Oncology, 2007, 8 (3) : 165 - 172